-Bloomberg
Why Apellis Pharmaceutical Shares Are Plunging Today
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary endpoint of GA lesion growth.